Literature DB >> 8395679

Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.

R Rosell1, S Li, Z Skacel, J L Mate, J Maestre, M Canela, E Tolosa, P Armengol, A Barnadas, A Ariza.   

Abstract

Mutated K-ras oncogenes have been detected in a third of lung adenocarcinomas, located usually in codon 12, its presence correlating negatively with survival. To further define the role of K-ras point mutations in non-small cell lung cancer, we studied the presence of mutated K-ras genes in surgical specimens from 66 patients. Polymerase chain reaction was performed from sections of formalin-fixed paraffin-embedded tissue. We screened for point mutations in codons 12, 13 and 61 of the K-ras gene by dot blot hybridization analysis with mutation-specific oligonucleotide probes. Ras gene mutations were present in 13 of 66 carcinomas (20%), nine in codon 12 and four in codon 61. Three squamous cell carcinomas harbored two different point mutations in K-ras codon 12. Mutated K-ras genes were found more frequently in squamous cell carcinomas (eight of 38) than in adenocarcinoma (three of 22). Analysis of nucleotide sequence disclosed a multifarious mutation pattern of K-ras codon 12, where the most common conversion was from glycine (GGT) to valine (GTT). K-ras point mutation positive subset had poorer survival, nine of the 13 patients died during the follow-up period as compared with 22 of 53 patients with no mutation in the K-ras gene (P = 0.01). The difference was also strikingly significant when stratified according to node status.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395679

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

Review 3.  New prognostic factors in resectable non-small cell lung cancer.

Authors:  E F Smit; H J Groen; T A Splinter; T Ebels; P E Postmus
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

4.  Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

Authors:  Athanasios C Tsiatis; Alexis Norris-Kirby; Roy G Rich; Michael J Hafez; Christopher D Gocke; James R Eshleman; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

Review 5.  Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.

Authors:  Mauricio Burotto; Anish Thomas; Deepa Subramaniam; Giuseppe Giaccone; Arun Rajan
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

Review 6.  Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer.

Authors:  R Milroy; F Macbeth
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

7.  Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer.

Authors:  Mark Shapiro; Gal Akiri; Cynthia Chin; Juan P Wisnivesky; Mary B Beasley; Todd S Weiser; Scott J Swanson; Stuart A Aaronson
Journal:  Ann Surg       Date:  2013-03       Impact factor: 12.969

Review 8.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

9.  K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma.

Authors:  E M Silini; F Bosi; N S Pellegata; G Volpato; A Romano; S Nazari; C Tinelli; G N Ranzani; E Solcia; R Fiocca
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs.

Authors:  E Tsuchiya; R Furuta; N Wada; K Nakagawa; Y Ishikawa; B Kawabuchi; Y Nakamura; H Sugano
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.